{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T21:10:17Z","timestamp":1689628217913},"reference-count":37,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.3892\/ol.2014.2664","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T12:04:12Z","timestamp":1415102652000},"page":"257-261","source":"Crossref","is-referenced-by-count":0,"title":["Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma"],"prefix":"10.3892","volume":"9","author":[{"given":"ZHUN","family":"WANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"QIAN-BO","family":"HAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JIA-LEI","family":"GU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XIN-MIN","family":"YU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XIAO-JIANG","family":"SUN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"QING-REN","family":"LIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JUN","family":"FANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUE-ZHEN","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YA-PING","family":"XU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WEI-MIN","family":"MAO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2014,11,4]]},"reference":[{"key":"key20180108103512_b1-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"key20180108103512_b2-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180108103512_b3-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"key20180108103512_b4-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.lungcan.2003.12.014","article-title":"Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, \u2018Iressa\u2019) on an expanded access study","volume":"44","author":"J\u00e4nne","year":"2004","journal-title":"Lung Cancer"},{"key":"key20180108103512_b5-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/annonc\/mdh010","article-title":"Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer","volume":"15","author":"Santoro","year":"2004","journal-title":"Ann Oncol"},{"key":"key20180108103512_b6-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1158\/1078-0432.CCR-04-0189","article-title":"Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer","volume":"10","author":"Park","year":"2004","journal-title":"Clin Cancer Res"},{"key":"key20180108103512_b7-ol-09-01-0257","first-page":"435","article-title":"Analysis of the response and toxicity to gefitinib of non-small cell lung cancer","volume":"25","author":"Konishi","year":"2005","journal-title":"Anticancer Res"},{"key":"key20180108103512_b8-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/107327480301000506","article-title":"Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution","volume":"10","author":"Simon","year":"2003","journal-title":"Cancer Control"},{"key":"key20180108103512_b9-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1158\/1078-0432.CCR-04-2149","article-title":"Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20180108103512_b10-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"key20180108103512_b11-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"key20180108103512_b12-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.lungcan.2010.08.016","article-title":"Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor","volume":"72","author":"Okamoto","year":"2011","journal-title":"Lung Cancer"},{"key":"key20180108103512_b13-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","article-title":"Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer","volume":"97","author":"Cappuzzo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"key20180108103512_b14-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2007.14.0111","article-title":"Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy","volume":"26","author":"Hirsch","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180108103512_b15-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jnci\/djh217","article-title":"Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer","volume":"96","author":"Cappuzzo","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"key20180108103512_b16-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1073\/pnas.0409773102","article-title":"ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines","volume":"102","author":"Engelman","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108103512_b17-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1200\/JCO.2005.00.992","article-title":"Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence","volume":"23","author":"Mitsudomi","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108103512_b18-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2005.01.388","article-title":"Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib","volume":"23","author":"Han","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108103512_b19-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1200\/JCO.2005.01.2823","article-title":"Southwest Oncology Group: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study","volume":"23","author":"Hirsch","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108103512_b20-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.1167.11.3","article-title":"The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers","volume":"11","author":"Tokumo","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20180108103512_b21-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-04-2081","article-title":"Predictors of the response to gefitinib in refractory non-small cell lung cancer","volume":"11","author":"Kim","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20180108103512_b22-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1200\/JCO.2005.01.0793","article-title":"Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer","volume":"23","author":"Takano","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108103512_b23-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","article-title":"Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib","volume":"12","author":"Riely","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20180108103512_b24-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20180108103512_b25-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","article-title":"Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy","volume":"47","author":"Trotti","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20180108103512_b26-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2005.05.153","article-title":"Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial","volume":"23","author":"Cella","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108103512_b27-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2407-7-51","article-title":"Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer","volume":"7","author":"Yokouchi","year":"2007","journal-title":"BMC Cancer"},{"key":"key20180108103512_b28-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180108103512_b29-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1185\/030079906X89847","article-title":"A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer","volume":"22","author":"Park","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"key20180108103512_b30-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.2005.05.4692","article-title":"Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations","volume":"24","author":"Inoue","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180108103512_b31-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/annonc\/mdi369","article-title":"Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience","volume":"16","author":"Hotta","year":"2005","journal-title":"Ann Oncol"},{"key":"key20180108103512_b32-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.lungcan.2012.09.016","article-title":"Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer","volume":"79","author":"Yang","year":"2013","journal-title":"Lung Cancer"},{"key":"key20180108103512_b33-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/cncr.21033","article-title":"High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib","volume":"103","author":"Omuro","year":"2005","journal-title":"Cancer"},{"key":"key20180108103512_b34-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1620\/tjem.214.359","article-title":"Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene","volume":"214","author":"Fukuhara","year":"2008","journal-title":"Tohoku J Exp Med"},{"key":"key20180108103512_b35-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2006.06.6126","article-title":"Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib","volume":"24","author":"Jackman","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180108103512_b36-ol-09-01-0257","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.lungcan.2008.10.028","article-title":"Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population","volume":"65","author":"Ma","year":"2009","journal-title":"Lung Cancer"},{"key":"key20180108103512_b37-ol-09-01-0257","article-title":"Prophylactic Cranial Irradiation (PCI) in Erlotinib\/Gefitinib-Responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)","author":"Ma","year":"2010","journal-title":"ClinicalTrialsgov Identifier: NCT01158170"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2014.2664\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T20:49:40Z","timestamp":1689626980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2014.2664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,4]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,11,4]]},"published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.3892\/ol.2014.2664"],"URL":"https:\/\/doi.org\/10.3892\/ol.2014.2664","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,4]]}}}